Zelira Therapeutics Ltd has released a press release.
Appendix 4D & FY22 Interim Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- December 2021 Quarterly Activities Report
- Zelira receives $1.2 million cash R&D Tax Incentive
- Partial Receipt Of Zeliras EDCDM Technology License Fee
- Zelira expands into NZ via exclusive distribution agreement
- ZLD Supports Levins Chronic Pain Trial Ethics Approval
Later from Zelira Therapeutics
- Zelira Therapeutics Ltd to acquire Health House
- ZLD: Zelira to acquire Health House International Limited
- March 2022 Quarterly Activities Report
- Hope 1 Longitudinal, Real-World Data Trial in ASD Results
- Zenivol Longitudinal, RWD Trial in Insomnia Results
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics